Efficacy analysis of decitabine based regimen for treatment of elderly patients with acute myeloid leukemia
10.3760/cma.j.issn.1009-9921.2017.08.006
- VernacularTitle:以地西他滨为主方案治疗初发老年人急性髓系白血病近期疗效分析
- Author:
Yong ZHANG
;
Hebing ZHOU
- Keywords:
Leukemia;
myeloid;
acute;
Aged;
Decitabine;
Adverse effects
- From:
Journal of Leukemia & Lymphoma
2017;26(8):472-474,482
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the security and efficacy in the elderly patients with acute myeloid leukemia (AML) treated by decitabine based regimen. Methods A retrospective analysis was carried out on 12 elderly patients with AML who were treated by decitabine alone or with low-dose chemotherapy in Beijing Luhe Hospital, Capital Medical University from June 2014 to December 2015. Results There were 6 patients of complete remission (CR), 5 patients of partial remission (PR), 1 patient of none remission (NR) after one course of chemotherapy. 1 case of 6 CR patients relapsed after 6 cycles of chemotherapy , others remained CR during the follow-up . Among 5 PR patients , 2 cases achieved CR , 1 patient relapsed after 2 cycles of chemotherapy and 2 patients relapsed after 3 cycles of chemotherapy. 1 patient remained NR after 2 cycles of chemotherapy and died of severe pulmonary infection. 3 of 4 complex karyotype patients had poor efficiency, and only 1 patient achieved CR but relapsed eventually. 7 patients achieved CR in patients with +8, -X or normal karyotype in the near future. The main adverse effects were bone marrow suppression and infection. All patients could tolerate. Conclusion Elderly patients with primary AML treated by decitabine alone or with low-dose chemotherapy show good effects, well tolerance and high safety, which could serve as the front-line treatment.
